Serum S100B levels after meningioma surgery: A comparison of two laboratory assays.
Serum S100B levels after meningioma surgery: A comparison of two laboratory assays.
复制标题
脑膜瘤手术后血清S100B水平：两种实验室测定的比较。
DOI：
10.1186/1472-6890-8-9
复制
发表时间：
2008-09-19
影响因子：
--
通讯作者：
Shoshan, Yigal
中科院分区：
文献类型：
--
作者：
Einav, Sharon;Itshayek, Eyal;Kark, Jeremy D;Ovadia, Haim;Weiniger, Carolyn F;Shoshan, Yigal
S100B蛋白是中枢神经系统损伤的潜在生物标志物。本研究定量比较了两种测定血清S100B浓度的方法。一项在单一三级医疗中心进行的前瞻性观察性研究。纳入了52例连续接受脑膜瘤手术的成人患者，这些患者提供血液样本用于测定S100B浓度。随机抽取80份样本（术前40份，术后40份）进行批量检测。每个样品被分成两个等分。采用ELISA （Sangtec）和商用试剂盒（罗氏Elecsys®）分析S100B浓度。统计分析包括回归模型和Bland-Altman分析。一个简洁的线性模型最能描述ELISA测定的商业试剂盒值的预测（y = 0.045 + 0.277*x, x = ELISA值，R2 = 0.732）。ELISA测定值往往高于商用试剂盒测定值。这种差异随着S100B浓度的增加而线性增加。当浓度高于0.7 μg/L时，配对测量结果始终超出Bland-Altman显示的一致限制。与其他使用替代测量方法的研究类似，使用Elecsys®未检测到与性别和年龄相关的血清S100B水平差异（p分别= 0.643和0.728）。虽然ELISA测定的血清S100B浓度与市售试剂盒之间存在普遍的线性关系，但ELISA值往往高于市售试剂盒的测量值，特别是在浓度超过0.7 μg/L时，这提示脑损伤。为了在临床实践中有效评估S100B对脑损伤的预测效度，需要商品化试剂盒的国际标准化。
S100B protein is a potential biomarker of central nervous system insult. This study quantitatively compared two methods for assessing serum concentration of S100B. A prospective, observational study performed in a single tertiary medical center. Included were fifty two consecutive adult patients undergoing surgery for meningioma that provided blood samples for determination of S100B concentrations. Eighty samples (40 pre-operative and 40 postoperative) were randomly selected for batch testing. Each sample was divided into two aliquots. These were analyzed by ELISA (Sangtec) and a commercial kit (Roche Elecsys®) for S100B concentrations. Statistical analysis included regression modelling and Bland-Altman analysis. A parsimonious linear model best described the prediction of commercial kit values by those determined by ELISA (y = 0.045 + 0.277*x, x = ELISA value, R2 = 0.732). ELISA measurements tended to be higher than commercial kit measurements. This discrepancy increased linearly with increasing S100B concentrations. At concentrations above 0.7 μg/L the paired measurements were consistently outside the limits of agreement in the Bland-Altman display. Similar to other studies that used alternative measurement methods, sex and age related differences in serum S100B levels were not detected using the Elecsys® (p = 0.643 and 0.728 respectively). Although a generally linear relationship exists between serum S100B concentrations measured by ELISA and a commercially available kit, ELISA values tended to be higher than commercial kit measurements particularly at concentrations over 0.7 μg/L, which are suggestive of brain injury. International standardization of commercial kits is required before the predictive validity of S100B for brain damage can be effectively assessed in clinical practice.